UroGen Pharma to Present at H.C. Wainwright BioConnect Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
- Fireside Chat
A live audio webcast will be available in the "Events and Presentations" section of UroGen’s investor website. A replay will be available for approximately 30 days.
About
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005188/en/
INVESTOR CONTACT:
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588
MEDIA CONTACT:
cindy.romano@urogen.com
908-963-7827
Source: